AOAli Amin Al Olama

Ali Amin Al Olama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Amin Al Olama has a total of 717 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data

    by Minh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, Eleanor I. Walsh, Emma L. Turner, J. Athene Lane, Richard M. Martin, David E. Neal, Jenny L. Donovan, Freddie C. Hamdy, et al.

    Background: A polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening. Methods: United Kingdom population incidence data (Cancer Research United Kingdom) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason score ≥7, stage T3–T4, PSA ≥10, or nodal/distant metastases). Using HRs estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age, when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-year-standard risk), was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups. Results: The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-year-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age. Conclusions: PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS. Impact: Personalized genetic risk assessments could inform prostate cancer screening decisions.


  • Open Access

    Simple MRI score aids prediction of dementia in cerebral small vessel disease

    by Ali Amin Al Olama, James M.S. Wason, Anil M. Tuladhar, Esther M.C. van Leijsen, Marisa Koini, Edith Hofer, Robin G. Morris, Reinhold Schmidt, Frank-Erik de Leeuw, Hugh S. Markus

    Objective To determine whether a simple small vessel disease (SVD) score, which uses information available on rapid visual assessment of clinical MRI scans, predicts risk of cognitive decline and dementia, above that provided by simple clinical measures. Methods Three prospective longitudinal cohort studies (SCANS [St George9s Cognition and Neuroimaging in Stroke], RUN DMC [Radboud University Nijmegen Diffusion Imaging and Magnetic Resonance Imaging Cohort], and the ASPS [Austrian Stroke Prevention Study]), which covered a range of SVD severity from mild and asymptomatic to severe and symptomatic, were included. In all studies, MRI was performed at baseline, cognitive tests repeated during follow-up, and progression to dementia recorded prospectively. Outcome measures were cognitive decline and onset of dementia during follow-up. We determined whether the SVD score predicted risk of cognitive decline and future dementia. We also determined whether using the score to select a group of patients with more severe disease would reduce sample sizes for clinical intervention trials. Results In a pooled analysis of all 3 cohorts, the score improved prediction of dementia (area under the curve [AUC], 0.85; 95% confidence interval [CI], 0.81–0.89) compared with that from clinical risk factors alone (AUC, 0.76; 95% CI, 0.71–0.81). Predictive performance was higher in patients with more severe SVD. Power calculations showed selecting patients with a higher score reduced sample sizes required for hypothetical clinical trials by 40%–66% depending on the outcome measure used. Conclusions A simple SVD score, easily obtainable from clinical MRI scans and therefore applicable in routine clinical practice, aided prediction of future dementia risk.


  • Open Access

    Publisher Correction: Shared heritability and functional enrichment across six solid cancers

    by Xia Jiang, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B. Kuchenbaecker, Joe Dennis, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Open Access

    Shared heritability and functional enrichment across six solid cancers

    by Xia Jiang, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B. Kuchenbaecker, Joe Dennis, et al.

    Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10−8), breast and ovarian cancer (rg = 0.24, p = 7 × 10−5), breast and lung cancer (rg = 0.18, p =1.5 × 10−6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10−4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.


  • Open Access

    Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    by Marco Matejcic, Edward J. Saunders, Tokhir Dadaev, Mark N. Brook, Kan Wang, Xin Sheng, Ali Amin Al Olama, Fredrick R. Schumacher, Sue A. Ingles, Koveela Govindasami, et al.

    The original version of this Article contained an error in the spelling of the author Manuela Gago-Dominguez, which was incorrectly given as Manuela G. Dominguez. This has now been corrected in both the PDF and HTML versions of the Article.


  • Open Access

    Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    by Marco Matejcic, Edward J. Saunders, Tokhir Dadaev, Mark N. Brook, Kan Wang, Xin Sheng, Ali Amin Al Olama, Fredrick R. Schumacher, Sue A. Ingles, Koveela Govindasami, et al.

    Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10−15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62–4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification.


  • Open Access

    Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    by Tokhir Dadaev, Edward J. Saunders, Paul J. Newcombe, Ezequiel Anokian, Daniel A. Leongamornlert, Mark N. Brook, Clara Cieza-Borrella, Martina Mijuskovic, Sarah Wakerell, Ali Amin Al Olama, et al.

    Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling.


  • Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci.

    by Rosalind Eeles, Ali Amin Al Olama, Sonja Berndt, Fredrik Wiklund, David V Conti, Mahbubl Ahmed, Sara Benlloch, Douglas Easton, Peter Kraft, Stephen J. Chanock, et al.

    1 Background: Currently genome-wide association studies (GWAS) have identified over 100 prostate cancer (PrCa) susceptibility loci, capturing 33% of the PrCa familial relative risk (FRR) in Europeans. To identify further susceptibility variants, we conducted a PrCa GWAS, larger than previous studies, comprising ~49,000 cases and ~29,000 controls among individuals of European and Asian descent using the OncoArray, a platform consisting of a 260K GWAS backbone and 310K custom content selected from previous GWAS and fine-mapping studies of multiple cancers ( http://epi.grants.cancer.gov/oncoarray/ ). Methods: Genotypes from the OncoArray were used to impute genotypes from ~70M variants using the October 2014 release of the 1000 genomes project as a reference, and then combined with several previous PrCa GWAS of European ancestry: UK stage 1 (1,906 cases/1,934 controls) and stage 2 (3,888 cases/3,956 controls); CaPS 1 (498 cases/502 controls) and CaPS 2 (1,483 cases/519 controls); BPC3 (2,137 cases/3,101 controls); NCI PEGASUS (4,622 cases/2,954 controls); and iCOGS (21,209 cases/ 20,440 controls). Risk analyses for overall PrCa risk, aggressive PrCa (several definitions defined by PrCa clinical characteristics), and Gleason score were performed. Logistic and linear regression summary statistics were meta-analysed using an inverse variance fixed effect approach. Results: We identified novel loci significantly associated ( P < 5.0x10-8) with overall PrCa (N = 65). Our novel findings are comprised of several missense variants, including a SNP in the ATM gene - a key member of the DNA repair pathway. When combined multiplicatively, the 65 novel PrCa loci identified here increases the captured heritability of PrCa, explaining 38.5% of the FRR when combining novel and previously identified PrCa loci. Conclusions: In risk stratification, men in the top 1% of the genetic risk score group have a relative risk of 5.6 fold for developing PrCa compared with the median risk group. These results will improve the utility of genetic risk scores for targeted screening and prevention for prostate cancer.

  • Prostate cancer meta-analysis from more than 143,000 men identifies 57 novel prostate cancer susceptibility loci

    by Rosalind Eeles, Fredrick R. Schumacher, Ali Amin Al Olama, Sonja I. Berndt, Fredrik Wilklund, David V. Conti, Mahbubl Ahmed, Sara Benlloch, Douglas F. Easton, Peter Kraft, et al.

  • Abstract 4606: Fine mapping of 64 prostate cancer GWAS regions identifies multiple novel association signals

    by Zsofia Kote-Jarai, Ali Amin Al Olama, Tokhir Dadaev, Dennis Hazelett, Qiuyan Li, Daniel Leongamornlert, Ed Saunders, Matthew Feedman, David Conti, Douglas Easton, et al.

    Genome-wide association studies (GWAS) have identified 100 common prostate cancer (PrCa) susceptibility loci to date. We performed comprehensive fine-mapping of 64 GWAS regions using genotyping and imputation to a 1000 Genomes reference panel for 25,779 PrCa cases and 26,218 controls of European ancestry from the PRACTICAL Consortium and two UK GWAS studies. In order to identify independent variants associated to PrCa, SNPs significant at P ≤10-4 were included in a stepwise logistic regression (SLR). Where the initial SLR identified multiple independent SNPs in a region, we re-analysed the region conditioning on the top hit. The adjusted results were subsequently trimmed using a P-value cut-off of ≤10-5 and a second SLR performed to identify independently significant index SNPs. We observed a single independent signal at 39 regions, with a novel, more significantly associated index SNP at 35 of these. Amongst these, we confirmed association in the European population for 2 loci previously reported in Asian GWAS. At 16 regions there was evidence for multiple independent signals, 14 of these contain newly identified additional significant associations. Functional annotation using data from ENCODE filtered for PrCa cell lines showed enrichment for overlap with bio-features within the fine-mapped SNP set and eQTL analysis identified novel candidate genes regulated by SNPs discovered in this study. Furthermore, we observed a 7% (from 32%-to 39%) improvement in the estimated proportion of familial relative risk explained through these refined and newly identified genetic variants. This study demonstrates the utility of fine-mapping, in silico functional annotation and eQTL approaches to narrow down the number of candidate functional variants. In addition, since a greater proportion of GWAS loci contained multiple independent risk variants than previously appreciated; this may explain a proportion of the missing heritability of complex diseases. Citation Format: Zsofia Kote-Jarai, Ali Amin Al Olama, Tokhir Dadaev, Dennis Hazelett, Qiuyan Li, Daniel Leongamornlert, Ed Saunders, Matthew Feedman, David Conti, Douglas Easton, Gerhard Coetzee, Rosalind Eeles, The PRACTICAL Consortium. Fine mapping of 64 prostate cancer GWAS regions identifies multiple novel association signals. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4606. doi:10.1158/1538-7445.AM2015-4606